Anti-SGPG antibody in CIDP: Nosological position of IgM anti-MAG/SGPG antibody-associated neuropathy

✍ Scribed by Yumi Tagawa; Nobuhiro Yuki; Koichi Hirata

• Publisher: John Wiley and Sons
• Year: 2000
• Tongue: English
• Weight: 152 KB
• Volume: 23
• Category: Article
• ISSN: 0148-639X
• DOI: 10.1002/(sici)1097-4598(200006)23:6<895::aid-mus8>3.0.co;2-g

✦ Synopsis

Polyneuropathy with monoclonal gammopathy usually is considered a nosological entity different from chronic inflammatory demyelinating polyneuropathy (CIDP). Criteria proposed by the American Academy of Neurology AIDS Task Force (1991), however, show monoclonal gammopathy to be a condition concurrent with CIDP. The purpose of this study was to clarify the nosological relationship between CIDP and IgM anti-myelinassociated glycoprotein (MAG)/sulfated glucuronyl paragloboside (SGPG)associated polyneuropathy. We investigated IgM anti-MAG/SGPG antibody in 85 CIDP patients by various methods, then examined the relation of M-protein to the presence of IgM anti-MAG/SGPG antibody. In our large study, 17 (20%) of 85 CIDP patients had high IgM anti-SGPG antibody titers in the enzyme-linked immunosorbent assay. This was confirmed by thinlayer chromatography-immunostaining for IgM anti-SGPG antibody and immunoblotting for IgM anti-MAG antibody. Immunoelectrophoresis and immunofixation, respectively, detected IgM M-protein in 6 (35%) and 13 (76%) of the 17 CIDP patients. We conclude that some patients with IgM anti-MAG/ SGPG antibody with or without monoclonal gammopathy may be diagnosed as having CIDP, when patients are diagnosed according to the current CIDP criteria.